Korea Investment CORP Sells 14,290 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Korea Investment CORP decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,603 shares of the biopharmaceutical company’s stock after selling 14,290 shares during the period. Korea Investment CORP owned about 0.07% of Alnylam Pharmaceuticals worth $22,026,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $1,045,822,000. Raymond James Financial Inc. purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $65,295,000. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $61,160,000. Proficio Capital Partners LLC grew its stake in shares of Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after acquiring an additional 192,916 shares during the period. Finally, Strategic Financial Concepts LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $41,529,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.9 %

NASDAQ ALNY opened at $268.46 on Friday. The stock has a market capitalization of $34.92 billion, a P/E ratio of -123.71 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a fifty day moving average of $259.86 and a 200-day moving average of $260.53.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on ALNY shares. HC Wainwright lifted their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a report on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Royal Bank of Canada boosted their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a report on Friday, March 21st. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a research report on Friday, March 21st. Finally, Sanford C. Bernstein decreased their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $312.30.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.